Wang Junming, Wang Pengfei, Shao Yiru, He Daikun
Center of Emergency and Critical Care Medicine, Jinshan Hospital, Fudan University, Shanghai 201508, China.
Research Center for Chemical Injury, Emergency and Critical Medicine of Fudan University, Shanghai 201508, China.
Pharmaceutics. 2023 Aug 17;15(8):2151. doi: 10.3390/pharmaceutics15082151.
Chronic inflammatory respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, present ongoing challenges in terms of effective treatment and management. These diseases are characterized by persistent inflammation in the airways, leading to structural changes and compromised lung function. There are several treatments available for them, such as bronchodilators, immunomodulators, and oxygen therapy. However, there are still some shortcomings in the effectiveness and side effects of drugs. To achieve optimal therapeutic outcomes while minimizing systemic side effects, targeted therapies and precise drug delivery systems are crucial to the management of these diseases. This comprehensive review focuses on the role of drug delivery systems in chronic inflammatory respiratory diseases, particularly nanoparticle-based drug delivery systems, inhaled corticosteroids (ICSs), novel biologicals, gene therapy, and personalized medicine. By examining the latest advancements and strategies in these areas, we aim to provide a thorough understanding of the current landscape and future prospects for improving treatment outcomes in these challenging conditions.
慢性炎症性呼吸道疾病,如哮喘、慢性阻塞性肺疾病(COPD)和囊性纤维化,在有效治疗和管理方面面临持续挑战。这些疾病的特征是气道持续存在炎症,导致结构改变和肺功能受损。针对这些疾病有多种治疗方法,如支气管扩张剂、免疫调节剂和氧疗。然而,药物的有效性和副作用仍存在一些不足。为了在尽量减少全身副作用的同时实现最佳治疗效果,靶向治疗和精确给药系统对于这些疾病的管理至关重要。这篇综述重点关注给药系统在慢性炎症性呼吸道疾病中的作用,特别是基于纳米颗粒的给药系统、吸入性糖皮质激素(ICSs)、新型生物制剂、基因治疗和个性化医疗。通过研究这些领域的最新进展和策略,我们旨在全面了解当前的情况以及在这些具有挑战性的病症中改善治疗效果的未来前景。